October 13, 2025 4:50pm

A “buy the dip” rebound from Friday’s selloff with softening China rhetoric

As important, live Israeli hostages returned

We are getting closer to Q3 LPS (loss-per-share) earnings releases waiting for coming share pricing debacles as the risk curve uplifts

Never leave an investor uninformed!  

Sector Q3 earnings begin with IQV Holdings (IQV) on 10/28 – key: catalysts needed!

RMi pre-open: Spring back … https://www.regmedinvestors.com/articles/14147

I believe earnings per share (EPS) estimates need to be revised along with the response to their share pricing declines upon their release to shake-off pipeline uncertainties

 

Monday: The Dow closed UP +587.98 points or +1.29%, the S&P closed UP +102.21 points or +1.56% while the Nasdaq closed UP +490.178points or +2.21%

  • Theme of the session: rebounding from Friday’s sell-off
  • The Russell 2000 jumped +2.8% after finishing Friday down 3%

Monday’s (my) 40-company covered sector’s advance/decline line opened positive with 21 incliners, 18 decliners and 1 flat ending with a neutral close of 20 incliners, 20 decliners and 0 flat

Metrics:  Monday, the RUT was up +66.82 points or +2.79%, the IBB was up +0.99 points or +0.66%, the XLV was down -0.16 points or -0.11%, the XBI was up +0.28 points or +0.27% while the VIX was down -2.61 points or -12.06% at 19.05

 

Q4 –1 neutral, 5 positive and 3 negative closes

Q3 – September - 1 holiday, 9 negative and 12 positive closes; August - 12 negative and 9 positive closes; July - 1 market holiday, 13 positive and 9 negative closes

 

Monday Closing UP (10 of 20) 

  • IQV Holdings (IQV +$5.60 after Friday -$4.83),
  • Alnylam Pharmaceuticals (ALNY +$4.80 after Friday +$3.51
  • Vericel (VCEL +$1.64),
  • Arrowhead Pharma (ARWR +$0.84),
  • BioLife Solutions (BLFS +$0.62),
  • Ultragenyx Pharma (RARE +$0.62),
  • uniQure NV (QURE +$0.57 after Friday -$2.10),
  • Regenxbio (RGNX +$0.47 after Friday -$1.25),
  • Cellectis SA (CLS +$0.42),
  • Generation Bio (GBIO +$0.38),

Flat (0)

Monday’s Closing DOWN (10 of 20): 

  • CRISPR Therapeutics (CRSP -$4.81 after Friday’s -$1.85),
  • Beam Therapeutics (BEAM -$0.93 after Friday’s -$1.55),
  • Intellia Therapeutics (NTLA -$0.76),
  • Adverum Biotechnologies (ADVM -$0.65),
  • Supernus Therapeutics (SUPN -$0.62),
  • Vertex (VRTX +$0.42 after Friday -$7.07),
  • AxoGen (AXGN -$0.40),
  • Capricor Therapeutics (CAPR -$0.37),
  • Entrada Therapeutics (TRDA -$0.28),
  • Fate Therapeutics (FATE -$0.245 after Friday’s +$0.025),

 

The Bottom Line: More of the … WHYs …

“Buy the dip” precedes earnings season releases after aa tough Friday.

It is still a "test” of how much risk investors were willing to take?

Problems still exist, with the always layers of uncertainty, with key economic data like CPI and retail sales delayed 

 

October: understand the “flow” …

  • 10/13 - Monday closed neutral with 20 positive, 20 negative and 0 flat

Last week:

  • 10/10 – Friday closed negative with 3 positive, 37 negative and 0 flat
  • 10/9 - Thursday closed positive with 21 positive, 19 negative and 0 flat
  • 10/8 – Wednesday closed positive with 29 positive, 10 negative and 1 flat
  • 10/7 – Tuesday closed negative with 15 positive, 25 negative and 0 flat
  • 10/6 – Monday closed negative with 17 positive, 22 negative and 1 flat

The previous week:

  • 10/3 – Friday closed positive with 27 positive, 10 negative and 3 flats
  • 10/2 - Thursday closed positive with 26 positive, 13 negative and 1 flat
  • 10/1 – Wednesday closed positive with 26 positive, 14 negative and 0 flat

 

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Monday: Alnylam Pharmaceuticals (ALNY), IQV Holdings (IQV) and Vericel (VCEL)
  • Friday: Alnylam Pharmaceuticals (ALNY), Compass Therapeutics (CMPX) and Fate Therapeutics (FATE)

The worst three (3) in the session:

  • Monday: CRISPR Therapeutics (CRSP), Beam Therapeutics (BEAM) and Adverum Biotechnologies (ADVM)
  • Friday: Lenz Therapeutics (LENZ), Vertex (VRTX) and IQV Holdings (IQV)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.